[go: up one dir, main page]

WO2015028957A3 - Compounds and methods for the treatment of respiratory diseases - Google Patents

Compounds and methods for the treatment of respiratory diseases Download PDF

Info

Publication number
WO2015028957A3
WO2015028957A3 PCT/IB2014/064103 IB2014064103W WO2015028957A3 WO 2015028957 A3 WO2015028957 A3 WO 2015028957A3 IB 2014064103 W IB2014064103 W IB 2014064103W WO 2015028957 A3 WO2015028957 A3 WO 2015028957A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
pulmonary
compounds
treatment
chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/064103
Other languages
French (fr)
Other versions
WO2015028957A2 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2015028957A2 publication Critical patent/WO2015028957A2/en
Publication of WO2015028957A3 publication Critical patent/WO2015028957A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for the treatment of respiratory diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of asthma, bronchiectasis, chronic obstructive lung disease including COPD, bronchitis and emphysema, chronic rhinosinusitis, hypersensitivity pneumonitis, lung cancer and neoplasms of respiratory and intrathoracic organs, lung fibrosis, chronic pleural disease, pneumoconiosis, pulmonary eosinophilia, pulmonary heart disease and diseases of pulmonary circulation including pulmonary embolism, pulmonary hypertension and rhinitis, sarcoidosis, sleep apnoea syndrome.
PCT/IB2014/064103 2013-08-29 2014-08-28 Compounds and methods for the treatment of respiratory diseases Ceased WO2015028957A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3872/CHE/2013 2013-08-29
IN3872CH2013 2013-08-29

Publications (2)

Publication Number Publication Date
WO2015028957A2 WO2015028957A2 (en) 2015-03-05
WO2015028957A3 true WO2015028957A3 (en) 2015-08-13

Family

ID=52587434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/064103 Ceased WO2015028957A2 (en) 2013-08-29 2014-08-28 Compounds and methods for the treatment of respiratory diseases

Country Status (1)

Country Link
WO (1) WO2015028957A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102701892B1 (en) * 2020-05-15 2024-09-02 제이투에이치바이오텍 (주) Erdosteine derivative and pharmaceutical composition containing the same
IT202000018286A1 (en) * 2020-07-28 2022-01-28 Edmond Pharma Srl PREPARATION OF ERDOSTEINE OR ONE OF ITS DERIVATIVES IN CONTINUOUS FLOW PROCESS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062205A2 (en) * 2008-09-08 2010-06-03 Rafifarm S.R.L. Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol
CN101941963A (en) * 2010-04-22 2011-01-12 浙江康乐药业股份有限公司 Synthesis method of erdosteine
WO2012069175A1 (en) * 2010-11-25 2012-05-31 Almirall, S.A. New pyrazole derivatives having crth2 antagonistic behaviour

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062205A2 (en) * 2008-09-08 2010-06-03 Rafifarm S.R.L. Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol
CN101941963A (en) * 2010-04-22 2011-01-12 浙江康乐药业股份有限公司 Synthesis method of erdosteine
WO2012069175A1 (en) * 2010-11-25 2012-05-31 Almirall, S.A. New pyrazole derivatives having crth2 antagonistic behaviour

Also Published As

Publication number Publication date
WO2015028957A2 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
SA519402319B1 (en) Tyrosine Amide Derivatives as RHO- KINASE Inhibitors
CY1122860T1 (en) 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(EXYL(2,3,4,5,6-PENTHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE -2-CARBOXAMIDE
MX2019005526A (en) Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors.
MX2015007797A (en) 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds.
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
PE20180799A1 (en) NRF2 REGULATORS
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
EA200900178A1 (en) Condensed Heterocyclic Derivatives and Their Application
JP2016500111A5 (en)
MX2014014106A (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease.
JP2016540749A5 (en)
MX342176B (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease.
EA032940B1 (en) Method for treatment of eosinophilic diseases using a glutarimide derivative compound
BR112015016184A2 (en) pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2013057251A3 (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
ATE530176T1 (en) USE OF COFFEE ACID AND ITS DERIVATIVES AGAINST CANCER
NZ709199A (en) Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015028957A3 (en) Compounds and methods for the treatment of respiratory diseases
MX2015008292A (en) Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease.
JP2007518798A5 (en)
NO20081483L (en) Combination of compounds that can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma
MX2017015192A (en) Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function.
WO2015008205A3 (en) Compositions and methods for the treatment of respiratory diseases
HK1219233A1 (en) Meropenem derivatives and uses thereof
WO2014174421A3 (en) Compositions and methods for the treatment of respiratory diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14839366

Country of ref document: EP

Kind code of ref document: A2